Ligation of CD23 triggers cAMP generation and release of inflammatory mediators in human monocytes.
Transduction through the CD23 molecule (Fc epsilon RII) was analyzed in normal human monocytes using monoclonal antibodies to CD23 (MHM6 and 135) and IgE/anti-IgE immune complexes. Monocytes expressing an increased amount of CD23 molecules were obtained by stimulation with IL-4 (30 U/ml). Anti-CD23 mAb as well as IgE/anti-IgE immune complexes were unable to induce any significant calcium mobilization [Ca2+]i in CD23-bearing monocytes whereas they elicited [Ca2+]i increase in B lymphocytes of the same donors. Despite their failure to induce calcium mobilization, the same CD23 ligands triggered a dose-dependent increase of intracellular cAMP, with a maximum 20 to 30 min after the onset of stimulation. This effect is mediated via CD23 inasmuch as: 1) F(ab)'2 fragments are as active as intact anti-CD23 mAb and 2) it is not observed in CD23- monocytes. The increase in cAMP was only partially altered in the presence of 1 microM indomethacin suggesting that it was not due to the release of PG. The possible role of CD23 in the activation of human monocytes was next documented by showing that anti-CD23 mAb and IgE/anti-IgE immune complexes induced the generation of IL-6 and of thromboxane B2 by CD23+ but not by CD23- monocytes. In addition, the IgE/anti-IgE-induced IL-6 production was potentiated in the presence of cAMP inducer such as the beta 2-adrenoceptor agonist salbutamol. These results indicate that ligation of CD23 induces cAMP generation in CD23+ human monocytes and that CD23 may regulate the IgE-dependent functions in normal human monocytes.
Paul-Eugene
N
N
Département d'Immunologie, Institut Henri Beaufour, Les Ulis, France.
Kolb
J P
JP
Abadie
A
A
Gordon
J
J
Delespesse
G
G
Sarfati
M
M
Mencia-Huerta
J M
JM
Braquet
P
P
Dugas
B
B
D000210:Acute-Phase Reaction / Q000276:immunology*; D000420:Albuterol / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000096:biosynthesis*; D004306:Dose-Response Relationship, Immunologic; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007073:Immunoglobulin E / Q000502:physiology; D007213:Indomethacin / Q000494:pharmacology; D015850:Interleukin-6 / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology; D009000:Monocytes / Q000378:metabolism*; D017455:Receptors, IgE / Q000502:physiology*; D015398:Signal Transduction / Q000276:immunology*; D013929:Thromboxane B2 / Q000096:biosynthesis
D015850:Interleukin-6; D008070:Lipopolysaccharides; D017455:Receptors, IgE; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; D007073:Immunoglobulin E; D004533:Egtazic Acid; D013929:Thromboxane B2; D000242:Cyclic AMP; D000420:Albuterol; D002118:Calcium; D007213:Indomethacin